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Abstract C9 is the most abundant protein of the membrane 
attack complex of complement. By means of limited proteolysis, 
different chromatographic techniques, a thiol-specific fluores- 
cence assay, amino acid analysis, and Edman degradation, 9 out 
of 12 disulfide bridges are definitely assigned (Cys22-Cys 57, 
Cys33-Cys ~, Cys67-Cys 73, Cys121-fys 16°, Cys233-Cys TM, Cys 359- 
Cys 3s4, Cys489-Cys 5°s, Cys492-Cys s°7, CysS°9-CysSIS). Weaker ev- 
idence permits to reduce the number of possible configurations for 
the remaining 3 cystines (CysS°-Cys 91, CysS*-Cys 1°4, Cys 9s- 
Cys ua, or CysS°-Cys 91, Cys86-Cys Ha, Cys9S-Cysl°4). These find- 
ings are disussed in comparison with the strongly related compo- 
nents C6, C7, C8~, and CSfl. 
Key words." Complement; C9; Disulfide bridge; Terminal 
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1. Introduction 
remaining 3 disulfides are dispersed across the comparatively 
heterlogous central part of the molecule (Pro ~ ~9 to Arg4S7). This 
area has been reported to contain the functionally important 
hinge region (Asn 22~ to Lys TM) [9], the membrane-spanning do- 
main (Va1293 to Leu TM) [19] and the CD59 binding site (Cys 359 
to Gly 411) [20]. 
Complement C9 is highly similar in structure to the other 
terminal complement components. Each type of module occur- 
ring in C9 is present again in varying number in C6, C7, C8~, 
or C8fl [21,22]. By sharing some of the substructures C9 is 
additionally related to several other complement compounds as 
well as to some proteins that are not associated with the com- 
plement system. 
Here we report the definite elucidation of 9 of the 12 disulfide 
bridges occurring in human C9 and present wo configurations 
of which one is likely to apply to the remaining 3 disulfides. We 
furthermore discuss our findings in relation to the other termi- 
nal complement components. 
With component C9 playing a key role in its action, the 
complement system is one of the most important effector mech- 
anisms of vertebrate immune response. After binding to a mem- 
brane-bound C5b-8 precursor complex, C9 unfolds and inserts 
into the lipid bilayer of the target cell [1-3]. Subsequently C9 
oligomerization occurs generating a functionally active cyto- 
toxic pore known as membrane attack complex (MAC) [4,5]. 
Human C9 is a single chain glycoprotein of an apparent 
molecular mass of about 71 kDa. It contains 538 amino acids 
including 24 half-cystines [(~8]. These are all engaged in intra- 
molecular disulfide bond formation. 
Earlier reports suggest hat there are at least five independ- 
ently folding domains in C9 [9,10]. The first two domains at the 
N-terminus have been recognized by sequence comparison as 
thrombospondin type I repeat (TSP I) (Asp 2t to Glu 77) [1 1 17] 
and low density lipoprotein receptor class A module (LDL A) 
(Asp 7s to Arg 118) [7]. Near the C-terminus is a moti f  (Lys 4ss to 
Lys s22) that is exhibiting partial sequence identity to the low 
density lipoprotein receptor class B domain (LDL B), also 
known as epidermal growth factor precursor type domain 
(EGF) [18]. Each of these modules contains 3 cystines. The 
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Abbreviations: MAC, membrane attack complex; TSP I, throm- 
bospondin type I repeat; LDL A, low density lipoprotein receptor class 
A module; LDL B, low density lipoprotein receptor class B module; 
EGF, epidermal growth factor; RP-HPLC; reversed phase high per- 
formance liquid chromatography; SDS-PAGE, polyacrylamide gel 
electrophoresis in the presence of sodium dodecyl sulfate; BNPS-ska- 
tole, 2-(2-nitrophenylsulfenyl)-3-methyl-3-bromoindolenine; SBD-F, 
ammonium 7-fluorobenz-2-oxa-l,3-diazole-4-sulfonate; DTT, dithio- 
threitol; PTH, phenylthiohydantoin. 
2. Materials and methods 
Cyanogen bromide was from Merck, BNPS-skatole from Pierce. 
Pepsin was obtained from Sigma, subtilisin and elastase from Serva. 
Thermolysin and Staphylococcus aureus V8 protease were of sequenc- 
ing grade supplied by Boehringer Mannheim. SBD-F was from Dojin, 
Kumamoto, Japan, and tri-n-butylphosphine from Aldrich. The rea- 
gents used for microsequencing were purchased from Applied Biosys- 
terns. The reagents used for RP-HPLC were lichrosolv grade products 
by Merck. All other chemicals were of analytical grade ordered either 
from Merck, Sigma, or Fluka. 
C9 was isolated from human plasma ccording to a published proce- 
dure [23]. SDS-PAGE was performed as described previously [24]. 
Cleavage with cyanogen bromide was carried out for 48 h in 70% 
trifluoroacetic a id in the dark at a reagent/substrate ratio of 5 : 1 (w/w). 
BNPS-skatole was applied in a 5 fold excess (w/w) for 72 h in 60% acetic 
acid, containing 0.2 M phenol. Enzymatic digestions were generally 
carried out at an enzyme/substrate ratio of 1:50 in the presence of 1 mM 
iodoacetamide to minimize disulfide interchange. Cleavage of native C9 
with elastase occurred in 0.2 M Tris-HCl, pH 8.8, for 72 h. Thermoly- 
sinolysis was performed in 10 mM borate buffer, pH 6.5, containing 50 
mM NaC1 and 2 mM CaCI 2 for 96 h. Subdigestion with V8- protease 
was done in 50 mM sodium phosphate buffer, pH 7.8 during 74 h. 
Subdigestion with subtilisin was carried out for 30 h at 37 °C in 0.1 M 
NH4HCO.~, pH 8.0. Subdigestion with pepsin was performed for 40 h 
at 37 °C in 10 mM HC1. 
Fragments generated by BNPS-skatole and cyanogen bromide were 
both separated by gel filtration on a Sephadex G-50 superfine column 
(1.8 x 90 cm) using 0.13 M formic acid as eluant. Enzymatic digests 
were usually separated first by RP- HPLC on a Bakerbond butyl col- 
umn (4.6 x 250 mm, wide pore, 5/lm; J.T. Baker Chemicals, Deventer, 
The Netherlands) in a Hewlett-Packard 1090 liquid chromatograph 
(Hewlett Packard, Waldbronn, Germany). Further purification was 
achieved applying Aquapore butyl, phenyl or octadecyl columns 
(2.1 x 100 mm, 7 jim) or an Aquapore RP-300 column (1.0 x 100 mm, 
7 /~m). In each case, an acetonitrile gradient in dilute aqueous tri- 
fluoroacetic acid was used. 
To monitor the cystine content an aliquot of each HPLC fraction was 
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either reacted with ammonium 7-fluorobenz-2- oxa-l,3-diazole-4-sul- 
fonate (SBD-F) [25] or alternatively subjected to amino acid analysis 
[26,27]. 
Disulfide-linked peptides thus identified were finally analyzed in a 
pulsed-liquid-phase sequenator 477A from Applied Biosystems com- 
bined with a model 120A PTH Analyzer using only DTT-free reagents 
[28]. Di-phenylthiohydantoin-cystine was identified after its release in 
the corresponding cycle as a double peak [29,30]. 
3. Resu l ts  
3.1. Cleavage of native C9 with BNPS-skatole 
Upon gel filtration the products obtained by BNPS-skatole 
cleavage yielded two pools, SKI and SK2. The later eluting 
SK2 consisted of two fragments in an approximate molar ratio 
of 2:1. The more prominent fragment ranged from Ala 43s to 
Lys 538 with the molecular mass of about 12 kDa, whereas the 
second one apparently extended from Gln ~ to Pro 175, corre- 
sponding to the 21 kDa species. BNPS-skatole generated a new 
N-terminus at Ser 31 in the larger fragment. Since C9 is N- 
terminally blocked, only two sequences were identified in SK2. 
After the sixth degradation cycle a distinct release of di-PTH- 
cystine, indicative of a disulfide link between Cys 33 and Cys 36, 
was observed (Table 1). 
3.2. Cleavage of native C9 with elastase 
Of the elastase fractions collected only E 18 showed distinct 
fluorescence values. Further analysis revealed that it mainly 
consisted of a single fragment with a molecular mass of about 
17 kDa and an N-terminus with the sequence Ser 18-His-Ile-Asp- 
Cys-Arg-Met-Ser-Pro-, thus implying that it essentially covered 
the TSP I and the LDL A region of C9. 
3.3. Subdigestion of elastase fraction El8 with V8 protease 
El8 was afterwards ubjected to V8 protease treatment. Cys- 
tine-containing fraction E18V7 contained two strands detecta- 
ble with the sequences Phesa-Gln-Cys86-Ser-Thr-Gly-Arg-Cys 91 
Table 1 
Edman degradation data and identification of disulfide bonds in human C9 
Peptide Fragmentation Subfragmentation Structural data Disulfide bond 
[ I 
SK2 BNPS-Skatole S3~QXDPCLR * 33 36 
I - - 7  
E 18V 10 Elastase A6°VGDRRQXVPTEPTXEDAE 67-73 
CB1P16 Cyanogen Pepsin p56KRXL 359 384 
Bromide I 
N380KDDCV * 
CB1V9 Cyanogen V8 Protease SI3SGSASHIDXR 22-57 
Bromide ] 
V48FGQFNGKRXTD 
CB1V17 Cyanogen V8 Protease F484SVRKCHTCQ * 489-505 
Bromide [ I 492-507 
DS°2GKX L XAXPF* 509 518 
I 
G515IAXE 
CB 1 T8 Cyanogen Thermolysin I2°DXR 22-57 
Bromide I 
F52NGKRCTDA 
ff--q 
CB1S11 Cyanogen Subtilisin E231Q X C EET 233-234 
Bromide 
I - - ]  
CB1S16 Cyanogen Subtilisin X33DPCL 33 36 
Bromide 
CB1S18 Cyanogen Subtilisin SHSEPRPPC * 121 160 
Bromide I 
XI60NRDRDG * 
CB1S19 Cyanogen Subtilisin SHSEPRPPCRD 121 160 
Bromide I 
Gt58LX 
I - - ]  
CB 1 $24 Cyanogen Subtilisin X67VPTEPCED 67-73 
Bromide 
[ m  I 
CB 1 $25 Cyanogen Subtilisin X33DPCLR 33-36 
Bromide 
CB2S 16 Cyanogen Subtilisin X 509-518 
Bromide I 
XS07ACPF 
I 
ISl6AC 
Edman degradation data of unreduced peptides; X denotes aCys residue xpected from the known sequence but not observed. C denotes the di-PTH 
derivative of cystine. Asteriks indicate chain ends that have not been rigorously identified. 
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Fig. 1. Schemanc representation f the disulfide bonding pattern of 
component C9 of human complement. Disulfides are indicated by dot- 
ted lines and the corresponding cysteine residues by the number in the 
C9 sequence, b and c represent the two arrangements that can be 
inferred from the data presented for the LDL A module. 
and Leu96-Arg-Cys98-Asn-Gly-Asp-Asn-Asp-Cysl°4-Gly-Asp- 
Phe-Ser-Asp-Glu- in about equimolar amounts. The obvious 
absence of di-PTH-cystine after the third degradation step, 
recorded in repeated experiments, led to the conclusion that 
Cys 86 is apparently bonded to another half-cystine than Cys ')~. 
EI8V10 comprised a fragment with the disulfide bridge be- 
tween Cys 67 and Cys 73. 
3.4. Cleavage of native C9 with cyanogen bromide 
Gel filtration of the cyanogen bromide digest yielded two 
pools, CB1 and CB2. SDS-PAGE and N-terminal sequence 
analysis indicated that pool CB1 essentially consisted of frag- 
ments derived from the N-terminal cluster of C9 (Gln I to Met 272 
or Met 287) with minor impurities originating from the central 
and C-terminal regions. Pool CB2 mainly contained a chain 
(Lys 464 to Lys 53s) that comprised the C-terminal EGF-like do- 
main. 
3.5. Subdigestion of cyanogen bromide fraction CB1 with pepsin 
Fraction CB1P16 contained two chains in a roughly equimo- 
lar ratio. The corresponding sequences were interpreted as 
Ile356-Lys-Arg-Cys-Leu and Asn38°-Lys-Asp-Asp-Cys-Val-, 
thus indicating a disulfide bond between Cys 359 and Cys ~s4. 
3.6. Subdigestion of cyanogen bromide fraction CB1 with V8 
protease 
CB1V9 comprised the disulfide bond between Cys 22 and 
Cys 57. This was derived from compositional nd sequence anal- 
ysis showing the presence of two chains extending from Ser ~3 
to Arg 23 and from Va148 to Asp 59. Fraction CB 1V 1 7 comprised 
a fragment with three disulfides. According to Edman degrada- 
tion and amino acid analysis the corresponding strands ranged 
from Phe 484 beyond Gln 493, from Asp 5°2 beyond Phe 511, and 
from Gly 515 to Glu 519, respectively. The liberation of di-PTH- 
cystine observed after the sixth, the eigth, and to a lesser extent 
after the ninth degradation step was fully compatible with the 
known cystine pattern of the epidermal growth factor type 
domain. 
3.7. Subdigestion of cyanogen bromide fraction CB1 with 
thermolysin 
N-Terminal sequence and compositional nalysis of fluores- 
cent fraction CB1T8 indicated the presence of a chain ranging 
from Ile 2~ to Arg 23, and a second one extending from Phe 52 to 
Ala 6°, thus confirming the earlier observed disulfide linkage 
between Cys 22 and Cys 57. 
3.8. Subdigestion of cyanogen bromide fraction CB1 with 
subtilisin 
N-Terminal sequence and compositional analysis of frag- 
ment CB1S1 1 showed a single chain extending from Glu TM to 
Thr 237, with the adjacent Cys 233 and Cys TM included. Consider- 
ing the release of di-PTH-cystine distinctly recorded after the 
fourth degradation cycle, the two half-cystines were conse- 
quently assigned to a very unusual vicinal disulfide bridge. 
Ed man degradation of CB 1 S 1 6 showed a single sequence rang- 
ing form Cys 33 tO Leu 37, supporting the earlier observation that 
Cys 33 forms a disulfide linkage to Cys 36. Fragment CB1S18 
consisted of two peptides with the N-termini SerllS-Glu-Pro - 
Arg-Pro-Pro-Cys 121- and Cysl6°-Asn-Arg-Asp-Arg-Asp-Gly-. 
Together with the sequences Ser~5-Glu-Pro-Arg-Pro-Pro - 
Cys TM and Gly158-Leu-Cys 16° found in CB1S19, this underlined 
the occurrence of a disulfide bond between Cys TM and Cys ~6°. 
The single strand detected in CB1S24 extended from Cys 67 to 
Asp 75, emphasizing the presence of a disulfide bond between 
Cy :  7 and Cys 73. N-Terminal sequence analysis and amino acid 
composition of CB1S25 revealed a single chain ranging from 
Cys 33 to Arg 38. This verified the previously postulated isulfide 
bond between Cys 33 and Cys 36. 
3.9. Subdigestion of cyanogen bromide Jraction CB2 with 
subtilisin 
Edman degradation and amino acid composition of fragment 
CB2S16 exhibited two sequences, one extending from Cys 5°7 to 
Phe 5~, and a second one ranging from Ile 516 to Cys 5~s. In agree- 
ment with the earlier established isulfide bonding pattern of 
the epidermal growth factor type domain, this indicated that 
Cys 5°9 is connected to Cys 5~8. 
4.  D iscuss ion  
Protease digestion experiments carried out earlier by various 
authors have indicated that native C9 is particularly resistant 
towards enzymatic leavage. This observation was critical to 
the present study and made necessary the application of a wide 
range of enzymes and reagents. 
First, experiments to establish the solar unidentified isul- 
fides in the N-terminal thrombospondin type I domain (Asp 2~ 
to Glu 77) involved treatment with BNPS-skatole, thus provid- 
ing preliminary evidence for the existence of a disulfide bond 
between Cys 33 and Cys 36. Data derived from analysis of frac- 
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tions CB1S16 and CB1S25 later confirmed that assignment. 
Pools denoted CB1V9 and CB1T8 contained peptides that en- 
closed the disulfide bond from Cys 22 to Cys 57. Fractions 
E18V10 and CB1S24 were shown to comprise the linkage be- 
tween the half-cystines in positions 67 and 73. These individual 
results taken together finally exhibit a 1~,, 2 3, 5-6 pattern 
for the cystine organisation within the TSP I segment of C9 
(Fig. la). 
The following low density lipoprotein receptor class A-ho- 
mologous domain (Asp TM to Arg ~s) also contains 6 half-cystines 
of unknown linking. Previous studies uggest he occurrence of 
a disulfide bridge between Cys 8° and Cys 91 [31,32]. As analysis 
of E18, CB 1, and SK2 showed, we were able to prepare samples 
from various digests that essentially contained both N-terminal 
domains. With sequences ranging from Aspv8 beyond Cys113, 
subsequent application of V8 protease on El8 even yielded, 
among others, several fragments that were almost fully identi- 
cal to LDL A. Further subfragmentation f those peptides, 
however, proved to be extremely difficult. In experiments not 
further eported here additional attempts were made using such 
powerful means as 2% formic acid (v/v), 6 M hydrochloric acid, 
subtilisin, or thermolysin. While hydrochloric acid effected an 
almost complete degradation even under altered reaction con- 
ditions in terms of acid concentration, temperature, and incu- 
bation time, neither formic acid nor subtilisin or thermolysin 
generated suitable peptides that would have allowed an un- 
ambiguous identification of disulfides by the tools at disposal 
in this study. Therefore only E18V7 gave further accounts of 
the disulfide structure in that particular egion. When that 
result is combined with the conclusions drawn from the cita- 
tions above, the number of possible disulfide configurations 
fulfilling both criteria is significantly reduced to a set of two 
situations. Assuming that Cys 8° is linked to Cys 91, Cys86 is then 
connected to either Cys 1°4 or Cys 113, and Cys 98 reciprocally to 
Cys I J3 or Cys TM. From a more general view, that actually means 
that either a 1-3, 2-5, 4-6 or a 1-3, 2-6, 4-5 pattern can be 
inferred for the LDL A module (Fig. lb,c). 
Table 2 
Prediction of the disulfides in C6, C7, C8~, and C8fl, as can 
be inferred from the investigations made of C9 
actually 
C9 C6 C7 C8~ C8fl 
Tsp I 22-57 61-96 6-41 9-44 11-46 
33 36 72 75 17 20 20 23 22 25 
67-73 106-112 51-57 54-60 56-62 
LDL A 80- 91 119-130 63-74 66-78 68-79 
86-104 125 143 69 87 72 91 73 92 
98-113 137-152 81-97 85-100 86-101 
or 
80-91 119 130 63 74 66-78 68 79 
86-113 125 152 6947 72 100 73 101 
98 104 137 143 81 87 85 91 86-92 
Central region 121 160 159 197 106-143 110-147 108-146 
233 234 
359-384 378-399 315-331 345-369 324-349 
LDL B (EGF) 489 505 502 518 435-451 469-485 451-467 
492 507 505 520 438-453 472-487 45~469 
509 518 522 531 455-464 489-498 471-480 
The half-cystines indicated are numbered proceeding from the N-termi- 
nus of the mature proteins [13,14,16,21,22,38]. The individual se- 
quences were compared with the use of the program package CLUS- 
TAL [37]. 
LDL A is followed by a long central stretch of amino acids 
(Pro 119 to Arg 487) that is lacking distinct modular features. It 
contains again 6 half-cystines. Their adjoinment has partially 
been postulated by means of limited proteolysis oon after the 
determination of the C9 sequence [7]. It has to be mentioned, 
however, that there have been uncertainties pecially as far as 
the linking of the adjacent Cys 233 and Cys TM is concerned [9]. 
The present study provides evidence that the disulfides in 
that particular egion are in fact arranged as previously sug- 
gested. Characterization f fractions CB1S18 and CB1S19 con- 
firmed the connection of Cys TM with Cys 16°. CB 1 P16 contained 
a fragment that included the disulfide bond between Cys 359 and 
Cys 384. Upon analysis ofCB1S11 we further demonstrated that 
Cys 233 is really bonded to Cys TM in a vicinal linkage (Fig. 
ld). 
Vicinal disulfide bridges have only rarely been encountered 
so far. Since the residues involved have to attain a highly 
strained conformation, such arrangements are extremely unsta- 
ble. In the context of C9, it is of special interest hat Cys z33 and 
Cys TM lie within a wide heterologous equence insertion of 
pronounced structural flexibility [9]. Accordingly, that region 
is considered to act as hinge when C9 unfolds upon interaction 
with the membrane-bound C5b-8 receptor complex. With re- 
gard to the vicinal disulfide pairing proved in this study, it is 
therefore attractive to relate the shape change of the molecule 
from a globular into an extended state after activation with a 
dissociation of the very cystine. The liberated sulfhydryl groups 
might subsequently form intermolecular cross-links with neigh- 
bouring C9 units, which are known to occur in high concentra- 
tion at the sites of MAC formation. The final consequences of 
such events would be imaged by the extremely resistant C9 
tubule. The notion of a local disulfide exchange is supported 
by studies carried out previously [33,34]. 
The 6 disulfides within the adjoining low density lipoprotein 
receptor class B module (Lys 488 to LysS22), synonymously 
known as epidermal growth factor domain, were shown to 
follow the general pattern for EGF [35,36]. CB2S16 contained 
a fragment comprising the disulfide-bridge between Cys 5°9 and 
Cys 518. Upon analysis of CB1V17 we were furthermore able to 
observe the disulfides between Cys 489 and Cys 5°5, between 
Cys 492 and Cys 5°7, and to a lesser extent again the link between 
Cys 5°9 and Cys 518. The well-known 1 3, 24 ,  5-6 disulfide ar- 
rangement is thus deduced (Fig. le). 
The entire length of the C9 sequence is highly conserved in 
all other terminal complement proteins. With the exception of 
two adjacent residues almost in the very center of the polypep- 
tide strand, all the half-cystines occurring in C9 appear in com- 
parable positions in C6, C7, C8c~, and C8fl. The disulfides 
assigned in this study can therefore be superimposed on the 
sequences of those proteins. Such a sequence comparison was 
carried out by means of the sequence alignment program pack- 
age CLUSTAL (PC/GENE) [37]. The data obtained are sum- 
marized as a final result in Table 2. 
Acknowledgements: We are particularly indebted to Dr. Jtirg Tschopp, 
University of Lausanne, for kindly providing us with a generous gift 
of complement component C9 at the very beginning of the project and 
for valuable advice concerning a later isolation in our own laboratory. 
We express our gratitude to Urs KS.mpfer and Daniel Wymann for 
skillful technical assistance. We are grateful to the Central Laboratory 
of the Blood Transfusion Service, Swiss Red Cross, for the generous 
supply of human plasma. 
12 S. Lengweiler et al./FEBS Letters 380 (1996) 8-12 
References 
[1] Podack, E.R. and Tschopp, J. (1982) Proc. Natl. Acad. Sci. USA 
79, 574-78. 
[2] Tschopp, J., Mtiller-Eberhard, H.J. and Podack, E.R. (1982) 
Nature 298, 534-538. 
[3] Tschopp, J., Podack, E.R. and Miiller-Eberhard, H.J. (1982) Proc. 
Natl. Acad. Sci. USA 79, 7474-7478. 
[4] Podack, E.R. (1984) J. Biol. Chem. 259, 8641 8647. 
[5] Tschopp, J., Engel, A. and Podack, E.R. (1984) J. Biol. Chem. 259, 
1922 1928. 
[6] DiScipio, R.G., Gehring, M.R., Podack, E.R., Kan, C.C., Hugli, 
T.E. and Fey, G.H. (1984) Proc. Natl. Acad. Sci. USA 81, 7298 
7302. 
[7] Stanley, K.K., Kocher, H.-P., Luzio, J.P., Jackson, P. and 
Tschopp, J. (1985) EMBO J. 4, 375-382. 
[8] Marazziti, D., Eggertsen, G., Fey, G.H. and Stanley, K.K. (1988) 
Biochemistry 27, 6529 6534. 
[9] Stanley, K.K. and Herz, J. (1987) EMBO J. 6, 1951 1957. 
[10] Stanley, K.K. (1988) Curr. Top. Microbiol. Immunol. 23, 451458. 
[11] Lawler, J. and Hynes, R.O. (1986) J. Cell. Biol. 103, 1635 1648. 
[12] Haefliger, J.-A., Tschopp, J., Nardelli, D., WahlL W., Kocher, 
H.-P., Tosi, M. and Stanley, K.K. (1987) Biochemistry 26, 3551 
3556. 
[13] Howard, O.M.Z., Rao, A.G. and Sodetz, J.M. (1987) Biochemis- 
try 26, 3565 3570. 
[14] Rao, A.G., Howard, O.M.Z., Ng, S.C., Whitehead, A.S., Colten, 
H.R. and Sodetz, J.M. (1987) Biochemistry 26, 3556 3564. 
[15] Patthy, L. (1988) J. Mol. Biol. 202, 689-696. 
[16] DiScipio, R.G., Chakravarti, D.N., Miiller-Eberhard, H.J. and 
Fey, G.H. (1988) J. Biol. Chem. 263, 549 560. 
[17] Chakravarti, D.N., Chakravarti, B., Parra, C.A. and Miiller-Eber- 
hard, H.J. (1989) Proc. Natl. Acad. Sci. USA 86, 2793 2803. 
[18] Stanley, K.K., Page, M., Campbell, A.K. and Luzio, J.P. (1986) 
Mol. Immunol. 23,451~,58 
[19] Peitsch, M.C., Amiguet, P., Guy, R., Brunner, J., Maizel, J.V.JR. 
and Tschopp, J. (1990) Mol. Immunol. 27, 589 602. 
[20] Chang, C.-P., Huesler, T., Zhao, J., Wiedmer, T. and Sims, P.J. 
(1994) J. Biol. Chem. 269, 26424-26430. 
[21] DiScipio, R.G. and Hugli, T.E. (1989) J. Biol. Chem. 264, 16197 
16206. 
[22] Haefliger, J.-A., Tschopp, J., Vial, N. and Jenne, D.E. (1989) 
J. Biol. Chem. 264, 18041-18051. 
[23] Biesecker, G. and Mfiller-Eberhard, H.J. (1980) J. Immunol. 124, 
1291 1296. 
[24] Laemmli, U.K. (1970) Nature 227, 680-685. 
[25] Sueyoshi, T., Miyata, T., Iwanaga, S., Toko'oka, T. and Imai, K. 
(1985) J. Biochem. (Tokyo) 97, 1811 1813. 
[26] Chang, J.-Y. and Knecht, R. (1991) Anal. Biochem. 197, 52-58. 
[27] Bidlingmeyer, B.A., Cohen, S.A. and Tarvin, T.L. (1984) J. Chro- 
matogr. 336, 93-104. 
[28] Hunkapiller, M.W., Wewick, R.M., Dreyer, W.J. and Hood, L.E. 
(1983) Methods Enzymol. 91,399~,13. 
[29] Lu, H.S., Klein, M.L., Everett, R.R. and Lai, P.-H. (1987) 
in: Proteins: Structure and Function (L'Italien, J. ed.) pp. 493 
501, Plenum Press, New York. 
[30] Marti, T., R6sselet, S.J., Titani, K. and Walsh, K.A. (1987) Bio- 
chemistry 26, 8099 8109. 
[31] Catterall, C.F., Lyons, A., Sim, R.B., Day, A.J. and Harris, T.J.R. 
(1987) Biochem. J. 242, 849 856. 
[32] Sire, R.B., Day, A.J., Moffat, B.E. and Fontaine, M. (1993) Meth- 
ods Enzymol. 223, 13 35. 
[33] Yamamoto, K., Kawashima, T. and Migita, S. (1982) J. Biol. 
Chem. 257, 8573 8576. 
[34] Yamamoto, K. and Migita, S. (1983) J. Biol. Chem. 258, 7887 
7889. 
[35] Savage, C.R., Hash, J.H. and Cohen, S. (1973) J. Biol. Chem. 248, 
7669 7672. 
[36] Hess, D,, Schaller, J. and Rickli, E.E. (1991) Biochemistry 30, 
2827 2833. 
[37] Higgins, D.G. and Sharp, P.M. (1988) Gene 73, 237 245. 
[38] White, R.V., Kaufman, K.M., Letson, C.S., Platteborze, EL. and 
Sodetz, J.M. (1994) J. Immunol. 152, 2501-2508. 
